Stay updated with breaking news from Apic Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is projected to reach USD 2,517 million by 2032, up from USD 1,413 million in 2022, growing at a CAGR of 6.1% during the forecast period from 2022 to 2032. This growth is driven by several key factors, including increasing awareness of AATD...
~ Announced FDA clearance of Investigational New Drug application for AMT-260 in refractory mesial temporal lobe epilepsy ~ ~ On track to provide clinical update from U.S. and European Phase I/II...
~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130 in Huntington’s disease showing preservation of function compared to baseline and clinical benefits...
~ Clinical update from U.S. Phase I/II trial in Huntington's disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in refractory